Division of Urology, European Institute of Oncology, IRCCS, Milan, Italy.
Istituto Clinico Città Studi, Milan, Italy.
Andrologia. 2020 Jul;52(6):e13613. doi: 10.1111/and.13613. Epub 2020 Apr 30.
We aimed to assess the incidence of prosthesis-related complications in patients who received a testicular prosthesis at the time of radical orchiectomy for testicular cancer and were then treated with chemotherapy (ChT) or radiotherapy (RT). We reviewed the records of the patients who underwent radical orchiectomy at our Institute since 1999; we also retrieved data from patients who underwent surgery elsewhere and then received ChT or RT at our Institution since 1999. We used the chi-square test to evaluate differences in the incidence of prosthesis-related complications between the groups. We retrieved the records of 587 patients; 393 had a testicular prosthesis implanted. Median follow-up was 57.7 months. One hundred thirty-eight patients (35.11%) received ChT, 129 RT (38.82%) and 10 (2.55%) both ChT and RT; of them, 6 (4.34%), 8 (6.20%) and 0 reported problems respectively. Seven (6.03%) of the 116 patients (29.52%) who had no further treatment had complications. The incidence of complications was not significantly different between patients who had no further treatment versus patients who underwent ChT (p = .75) or RT (p = .83). Testicular prosthesis insertion at the time of radical orchiectomy is safe even in patients subsequently undergoing ChT or RT.
我们旨在评估在因睾丸癌行根治性睾丸切除术时同时接受睾丸假体植入、随后接受化疗(ChT)或放疗(RT)的患者中与假体相关的并发症发生率。我们回顾了自 1999 年以来在我院行根治性睾丸切除术的患者记录;我们还检索了自 1999 年以来在其他地方手术、随后在我院接受 ChT 或 RT 的患者的数据。我们使用卡方检验评估两组间与假体相关的并发症发生率的差异。我们共检索了 587 例患者的记录,其中 393 例植入了睾丸假体。中位随访时间为 57.7 个月。138 例患者(35.11%)接受了 ChT,129 例接受了 RT(38.82%),10 例(2.55%)同时接受了 ChT 和 RT;其中,6 例(4.34%)、8 例(6.20%)和 0 例分别报告出现问题。116 例(29.52%)未接受进一步治疗的患者中有 7 例(6.03%)出现并发症。与接受 ChT(p=0.75)或 RT(p=0.83)的患者相比,未接受进一步治疗的患者的并发症发生率无显著差异。即使在随后接受 ChT 或 RT 的患者中,根治性睾丸切除术中植入睾丸假体也是安全的。